SCYNEXIS Inc (NASDAQ:SCYX) CEO Marco Taglietti acquired 25,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The stock was purchased at an average cost of $1.63 per share, for a total transaction of $40,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 506,000 shares of the company’s stock, valued at approximately $824,780. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
SCYNEXIS stock opened at $1.65 on Friday. The stock has a market cap of $82.74 million, a P/E ratio of -3.37 and a beta of 2.38. SCYNEXIS Inc has a 52 week low of $0.35 and a 52 week high of $2.15. The company has a current ratio of 8.76, a quick ratio of 8.76 and a debt-to-equity ratio of 0.48.
A number of brokerages have recently weighed in on SCYX. Zacks Investment Research lowered SCYNEXIS from a “buy” rating to a “hold” rating in a report on Friday, February 8th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price objective on shares of SCYNEXIS in a report on Tuesday, April 16th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $4.93.
COPYRIGHT VIOLATION NOTICE: This report was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/21/insider-buying-scynexis-inc-scyx-ceo-purchases-40750-00-in-stock.html.
SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.